
## Gerit-Holger Schernthaner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6982706/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. American Journal of Hematology, 2011, 86, 533-539.	4.1	254
2	Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015, 125, 901-906.	1.4	239
3	Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leukemia Research, 2001, 25, 529-536.	0.8	206
4	Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. Journal of Allergy and Clinical Immunology, 2002, 110, 102-109.	2.9	156
5	Detection of molecular targets on the surface of CD34+/CD38â^' stem cells in various myeloid malignancies. Leukemia and Lymphoma, 2006, 47, 207-222.	1.3	140
6	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thrombosis and Haemostasis, 2020, 120, 1597-1628.	3.4	131
7	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood, 2001, 98, 2200-2209.	1.4	130
8	Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leukemia Research, 2001, 25, 563-570.	0.8	124
9	Elevated Fetuin-A Concentrations in Morbid Obesity Decrease after Dramatic Weight Loss. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4877-4881.	3.6	97
10	Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013. Diabetes Care, 2013, 36, S155-S161.	8.6	86
11	Epidemiology of peripheral artery disease in Europe: VAS Educational Paper. International Angiology, 2018, 37, 327-334.	0.9	86
12	Correlation of Different Circulating Endothelial Progenitor Cells to Stages of Diabetic Retinopathy: First In Vivo Data. , 2009, 50, 392.		79
13	Effect of Massive Weight Loss induced by Bariatric Surgery on Serum Levels of Interleukin-18 and Monocyte-Chemoattractant-Protein-1 in Morbid Obesity. Obesity Surgery, 2006, 16, 709-715.	2.1	77
14	Detection of Novel CD Antigens on the Surface of Human Mast Cells and Basophils. International Archives of Allergy and Immunology, 2002, 127, 299-307.	2.1	76
15	Peptide YY and Glucagon-like Peptide-1 in Morbidly Obese Patients Before and After Surgically Induced Weight Loss. Obesity Surgery, 2007, 17, 1571-1577.	2.1	72
16	YKL-40 is Elevated in Morbidly Obese Patients and Declines After Weight Loss. Obesity Surgery, 2009, 19, 1557-1563.	2.1	69
17	Ghrelin and Obestatin Levels in Severely Obese Women Before and After Weight Loss After Roux-en-Y Gastric Bypass Surgery. Obesity Surgery, 2009, 19, 29-35.	2.1	63
18	Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery. Obesity Surgery, 2018, 28, 643-648.	2.1	63

#	Article	IF	CITATIONS
19	Fetuin-A Levels Are Increased in Patients With Type 2 Diabetes and Peripheral Arterial Disease. Diabetes Care, 2011, 34, 156-161.	8.6	59
20	Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood, 2001, 98, 2580-2583.	1.4	58
21	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leukemia Research, 2017, 59, 47-54.	0.8	58
22	The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diabetes and Vascular Disease Research, 2014, 11, 306-323.	2.0	55
23	Endothelial Progenitor Cells Are Related to Glycemic Control in Children With Type 1 Diabetes Over Time. Diabetes Care, 2013, 36, 1647-1653.	8.6	49
24	Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood, 2001, 98, 3784-3792.	1.4	48
25	In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Experimental Hematology, 2010, 38, 744-755.	0.4	46
26	Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. British Journal of Haematology, 2003, 120, 257-265.	2.5	44
27	Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. European Journal of Clinical Investigation, 2006, 36, 395-401.	3.4	44
28	A case of â€~̃smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leukemia Research, 2001, 25, 627-634.	0.8	43
29	Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?. Nephrology Dialysis Transplantation, 2010, 25, 2044-2047.	0.7	38
30	YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetes. Atherosclerosis, 2012, 222, 557-563.	0.8	38
31	Circulating levels of MCPâ€1 are increased in women with gestational diabetes. Prenatal Diagnosis, 2008, 28, 845-851.	2.3	34
32	A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leukemia Research, 2002, 26, 601-606.	0.8	32
33	Insulin Resistance and Inflammation in the Early Phase of Type 2 Diabetes: Potential for Therapeutic Intervention. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 30-40.	1.2	31
34	Circulating Angiopoietic Cells and Diabetic Retinopathy in Type 2 Diabetes Mellitus, with or without Macrovascular Disease. , 2011, 52, 4655.		31
35	Homocyst(e)ine-Lowering Therapy Does Not Affect Plasma Asymmetrical Dimethylarginine Concentrations in Patients with Peripheral Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2175-2178.	3.6	30
36	Activation of Human Mast Cells through Stem Cell Factor Receptor (KIT) Is Associated with Expression of bcl-2. International Archives of Allergy and Immunology, 2002, 129, 228-236.	2.1	29

#	Article	IF	CITATIONS
37	The right place for metformin today. Diabetes Research and Clinical Practice, 2020, 159, 107946.	2.8	29
38	Increase of Osteopontin Plasma Concentrations After Bariatric Surgery Independent from Inflammation and Insulin Resistance. Obesity Surgery, 2009, 19, 351-356.	2.1	28
39	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Clinical Therapeutics, 2016, 38, 1288-1298.	2.5	28
40	Diabetic nephropathy: new approaches for improving glycemic control and reducing risk. Journal of Nephrology, 2013, 26, 975-985.	2.0	28
41	Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3. Journal of Leukocyte Biology, 2003, 73, 107-117.	3.3	27
42	Relationship of Androgens to Insulin Resistance and Chronic Inflammation in Morbidly Obese Premenopausal Women: Studies before and after Vertical Banded Gastroplasty. Obesity Surgery, 2006, 16, 1214-1220.	2.1	27
43	Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease. Annals of Medicine, 2017, 49, 291-298.	3.8	26
44	Frequency of Hypoglycaemia after Different Bariatric Surgical Procedures. Obesity Facts, 2019, 12, 397-406.	3.4	26
45	Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. European Journal of Clinical Investigation, 2012, 42, 470-477.	3.4	25
46	Stem Cell Factor-induced Bone Marrow Mast Cell Hyperplasia Mimicking Systemic Mastocytosis (SM): Histopathologic and Morphologic Evaluation with Special Reference to Recently Established SM-criteria. Leukemia and Lymphoma, 2002, 43, 575-582.	1.3	24
47	Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010. Diabetes Care, 2011, 34, S355-S360.	8.6	24
48	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. Acta Diabetologica, 2009, 46, 173-181.	2.5	22
49	FABP4 and Cardiovascular Events in Peripheral Arterial Disease. Angiology, 2018, 69, 424-430.	1.8	22
50	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. Thrombosis and Haemostasis, 2021, 121, 992-1007.	3.4	21
51	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. Atherosclerosis, 2022, 348, 25-35.	0.8	18
52	Expression of Cell Surface Antigens on Mast Cells: Mast Cell Phenotyping. , 2006, 315, 077-090.		16
53	No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease. European Journal of Clinical Investigation, 2006, 36, 333-339.	3.4	16
54	YKLâ€40 concentrations are not elevated in gestational diabetes. European Journal of Clinical Investigation, 2010, 40, 339-343.	3.4	15

#	Article	IF	CITATIONS
55	Predictive power of novel and established obesity indices for outcome in PAD during a five-year follow-up. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1179-1187.	2.6	13
56	Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes. Heart and Vessels, 2020, 35, 52-58.	1.2	10
57	Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRPα), CD47, and SHP-1. Journal of Leukocyte Biology, 2005, 77, 984-992.	3.3	9
58	YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients. Atherosclerosis, 2018, 274, 152-156.	0.8	8
59	How many more data is required to give the kidney the attention it deserves? Time to act for the "Big Five―of cardiovascular risk. Atherosclerosis, 2020, 297, 146-148.	0.8	8
60	Milestones in thromboangiitis obliterans: a position paper of the VAS-European independent foundation in angiology/vascular medicine. International Angiology, 2021, 40, 395-408.	0.9	8
61	Angiopoietin-2 and Survival in Peripheral Artery Disease Patients. Thrombosis and Haemostasis, 2018, 47, 791-797.	3.4	7
62	YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease. Anatolian Journal of Cardiology, 2016, 16, 959.	0.9	7
63	Signal Transduction—Associated and Cell Activation—Linked Antigens Expressed in Human Mast Cells. International Journal of Hematology, 2002, 75, 357-362.	1.6	6
64	Albuminuria in Patients with Morbid Obesity and the Effect of Weight Loss Following Bariatric Surgery. Obesity Surgery, 2019, 29, 3581-3588.	2.1	6
65	GlycA for long-term outcome in T2DM secondary prevention. Diabetes Research and Clinical Practice, 2021, 171, 108583.	2.8	6
66	Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. Blood, 2014, 124, 1800-1800.	1.4	5
67	Reduced adiponectin receptor signalling accelerates atherosclerosis and may worsen the outcome in type 2 diabetes mellitus $\hat{a} \in \hat{a}$ Another one of those missing links?. Atherosclerosis, 2013, 229, 30-31.	0.8	4
68	Finally, the big picture of morbidity and mortality in peripheral arterial disease?. Atherosclerosis, 2020, 293, 92-93.	0.8	4
69	Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality. Atherosclerosis, 2021, 317, 41-46.	0.8	4
70	Metformin – from Devil to Angel. , 2007, , 77-86.		4
71	Calcification Propensity in Serum and Cardiovascular Outcome in Peripheral Artery Disease. Thrombosis and Haemostasis, 2022, 122, 1040-1046.	3.4	4
72	Gender, metabolic control and carotid intima-media-thickness in children and adolescents with type 1 diabetes mellitus. Wiener Klinische Wochenschrift, 2015, 127, 116-123.	1.9	3

#	Article	IF	CITATIONS
73	Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control. Diabetes and Vascular Disease Research, 2020, 17, 147916412091484.	2.0	3
74	Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery. Obesity Surgery, 2021, 31, 2545-2550.	2.1	3
75	Research update for articles published in <scp>EJCI</scp> in 2011. European Journal of Clinical Investigation, 2013, 43, 1097-1110.	3.4	2
76	Moderate alcohol consumption shifts to an atheroprotective phenotype: A glass of wine keeps atherosclerosis in check?. Atherosclerosis, 2016, 254, 305-306.	0.8	2
77	Peripheral arterial disease and loss of physical function: Just two old friends?. Atherosclerosis, 2017, 257, 246-247.	0.8	2
78	Vascular peroxidase 1 is independently associated with worse kidney function in patients with peripheral artery disease. Journal of Nephrology, 2021, 34, 165-172.	2.0	2
79	Angiogenin—A Proposed Biomarker for Cardiovascular Disease—Is Not Associated With Long-Term Survival in Patients With Peripheral Artery Disease. Angiology, 2021, 72, 855-860.	1.8	2
80	Do we need a new classification system for arteriosclerotic lesions in crural limb ischemia? Pros and Cons. Atherosclerosis, 2016, 251, 493-494.	0.8	1
81	Hypertension and Diabetes. , 2007, , 417-436.		1
82	Statin initiation in dialysis patients: The hardship of non-prescription. Atherosclerosis, 2021, 337, 53-56.	0.8	1
83	Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality. Atherosclerosis, 2022, 341, 7-12.	0.8	1
84	High-Density Lipoprotein Particle Subclasses in Statin-Treated Patients with Peripheral Artery Disease Predict Long-Term Survival. Thrombosis and Haemostasis, 2022, 122, 1804-1813.	3.4	1
85	Chronic kidney disease, mineral bone disease and future risk of peripheral artery disease: Do associations rule?. Atherosclerosis, 2017, 267, 153-155.	0.8	0
86	Peripheral arterial disease outcomes and association with suPAR: AÂbridge to myeloid precursors or mast cells or both?. Atherosclerosis, 2017, 264, 77-78.	0.8	0
87	Chronic lung disorders and abdominal aortic aneurysms: An old clinicalÂobservation now proven?. Atherosclerosis, 2018, 268, 191-192.	0.8	0
88	FP348SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (suPAR) IS ASSOCIATED WITH KDIGO CHRONIC KIDNEY DISEASE STAGE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
89	Gestational diabetes and maternal obesity suggestively priming children's premature atherosclerosis: Is it the mother fault?. Atherosclerosis, 2019, 284, 214-215.	0.8	0
90	sCD40L: An overestimated marker for cardiovascular risk prediction?. Atherosclerosis, 2019, 291, 122-123.	0.8	0

#	Article	IF	CITATIONS
91	From the eye into the foot?. Atherosclerosis, 2020, 294, 41-43.	0.8	0
92	The enigma to best screen, evaluate and diagnose peripheral artery disease. Atherosclerosis, 2020, 315, 79-80.	0.8	0
93	New horizons for mortality risk stratification in PAD: Are targeted multiplex proteomics the next step?. Atherosclerosis, 2020, 311, 98-99.	0.8	0
94	The peripheral perfusion between two extremes: Is a fraction of the pulse wave enough information?. Atherosclerosis, 2020, 304, 53-54.	0.8	0
95	Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes. Vascular Medicine, 2021, 26, 11-17.	1.5	0
96	Peripheral artery disease and depression: Prerequisites for a lose-lose situation?. Atherosclerosis, 2021, 329, 30-31.	0.8	0
97	YKL-40: an innocent bystander or an active threat in acute and chronic cardiac diseases?. Polish Archives of Internal Medicine, 2018, 128, 636-637.	0.4	0